Shilpa Sambashivan, new Nura Bio CEO
Nura Bio raises $68M for clinical tests of SARM1 inhibitor to potentially slow or prevent nerve degeneration
A promising new approach that could slow, stop or prevent nerves from dying may get its first test in patients next year.
Nura Bio, a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
